Cytokinetics Inc
NASDAQ:CYTK
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.22
108.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cytokinetics Inc
Cytokinetics Inc
Revenue
Cytokinetics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cytokinetics Inc
NASDAQ:CYTK
|
Revenue
$3.2m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-24%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$55.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$32.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$10.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
Cytokinetics Inc
Glance View
Cytokinetics Inc., a clinical-stage biopharmaceutical company, is at the forefront of developing impactful treatments for muscle diseases, leveraging its pioneering expertise in muscle biology and discovery. Founded in 1999 and headquartered in South San Francisco, California, Cytokinetics focuses on harnessing the power of muscle function through its innovative therapies. The company’s lead product candidates, including omecamtiv mecarbil and reldesemtiv, are specifically designed to improve muscle performance in patients suffering from serious conditions like heart failure and amyotrophic lateral sclerosis (ALS). As the demand for effective treatments grows, Cytokinetics is leading the charge to enhance muscle function, aiming not just to prolong life, but to improve patients' quality of life. For investors, Cytokinetics presents a unique opportunity within the growing biopharmaceutical market. The company has strategically partnered with industry leaders, including Amgen, to accelerate the development of its therapeutic portfolio, significantly bolstering its credibility and pipeline potential. With increasing recognition of the importance of muscle health, Cytokinetics stands at an advantageous juncture, positioned to leverage its scientific know-how to unlock substantial value. As clinical trials progress and the company moves closer to potential commercialization, investors have the potential to benefit from Cytokinetics’ innovative approach to addressing unmet medical needs, making it a compelling consideration for those looking to invest in the future of healthcare innovation.
See Also
What is Cytokinetics Inc's Revenue?
Revenue
3.2m
USD
Based on the financial report for Sep 30, 2024, Cytokinetics Inc's Revenue amounts to 3.2m USD.
What is Cytokinetics Inc's Revenue growth rate?
Revenue CAGR 10Y
-24%
Over the last year, the Revenue growth was -59%. The average annual Revenue growth rates for Cytokinetics Inc have been -47% over the past three years , -36% over the past five years , and -24% over the past ten years .
You don't have any saved screeners yet
